Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis (DOVE)
A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Sponsor: Scynexis, Inc.
Listed as NCT03253094, this PHASE2 trial focuses on Candida Vulvovaginitis and remains completed. Sponsored by Scynexis, Inc., it has been updated 12 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2019 — Nov 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Scynexis, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .